Coave Therapeutics
  • About us
    • Our Team
    • Our Board of Directors
    • Our Scientific Advisory Board
  • Technology
    • Meet ALIGATER
    • Manufacturing
  • Pipeline
    • Ocular Diseases
  • News
    • Press Releases
  • Careers
  • Contact
Coave Therapeutics
  • About us
    • Our Team
    • Our Board of Directors
    • Our Scientific Advisory Board
  • Technology
    • Meet ALIGATER
    • Manufacturing
  • Pipeline
    • Ocular Diseases
  • News
    • Press Releases
  • Careers
  • Contact
  • Home
  • Press Releases
  • Events
  • Careers

Press Releases

16 September 2026

Coave Therapeutics Strengthens Leadership Team to Advance Lead Gene Therapy Program into the Clinic

Read more
28 April 2026

Coave Therapeutics to unveil OneAAV™ universal capsid at ASGCT 2026, paving the way for third generation gene therapy vectors

Read more
22 April 2026

Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

Read more
14 November 2025

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery

Read more
7 October 2025

Coave Therapeutics demonstrates superiority of its novel suprachoroidal capsidat ESGCT Congress 2025

Read more
20 May 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases

Read more
9 May 2025

Coave Therapeutics Launches coAAV-CSF-01, a Novel Brain-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases

Read more
23 April 2025

Coave Therapeutics Expands into the US with Strategic Appointment of Romain Pettenaro as VP of Business Development

Read more
9 April 2025

Coave Therapeutics to Attend Upcoming Conferences

Read more
21 October 2024

Coave Therapeutics Showcases Breakthrough in Peptide-Based Conjugated AAV Vectors Using ALIGATER™ Platform in a Late-Breaking Abstract at ESGCT 2024

Read more

COAVE Tx

63bis avenue Ledru Rolin
75012 Paris
France

  • About us
  • Technology
  • Pipeline
  • News
  • Careers
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • Cookie policy

Follow us

Copyright 2021-2026 Coave Therapeutics. Coave TX is a Trademark of Horama SA. All Right Reserved.
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}